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Introduction: We evaluated the expression of the oncofetal protein 
IMP3 in a series of neuroendocrine tumors of the lung, correlating our 
results with proliferating index Ki67 and with the expression of the 
two most studied stem cell markers in lung cancer, Nanog and Oct3/4.
Methods: A total of 74 patients with a diagnosis of neuroendocrine 
tumor including 46 cases of typical carcinoid, nine cases of atypical 
carcinoids, 13 cases of large cell neuroendocrine carcinomas and six 
cases of small cell carcinomas were enrolled.
Results: IMP3 was expressed in 50% of small cell carcinomas, 84% 
of large cell neuroendocrine carcinomas, 55% of atypical carcinoids 
and 10% of typical carcinoids. IMP3-positive cases showed signifi-
cantly decreased overall and disease-free survival time compared 
with IMP3-negative cases. Nanog was expressed in 50% of small cell 
carcinomas, 31% of large cell neuroendocrine carcinomas, 33% of 
atypical carcinoids and 15% of typical carcinoids, and 68% of IMP3-
positive tumors were also enriched for Nanog expression. Conversely, 
Oct3/4 expression could not be detected in all the analyzed series. 
When combining Ki67 and IMP3 expression we demonstrated that all 
the cases with a Ki67 index higher than 4% were also IMP3-positive, 
and their simultaneous expression was a poor prognostic factor.
Conclusions: IMP3 is a marker of poor outcome in lung neuroen-
docrine tumors; its correlation with Nanog expression suggest an 
implication of IMP3 in stem cell processes and its association with 
a Ki67 labeling index higher than 4% stratifies a subset of atypical 
carcinoids with a higher risk of recurrence and mortality.
Key Words: IMP3, Lung neuroendocrine tumors, Nanog, Oct3/4.
(J Thorac Oncol. 2014;9: 1656–1661)
According to World Health Organization (WHO) classifica-tion, neuroendocrine tumors of the lung comprises four 
distinct entities, typical carcinoids, atypical carcinoids, small 
cell carcinomas, and large cell neuroendocrine carcinomas, 
which differ in histological and immunohistochemical fea-
tures and biological behavior.
Overall, the 5-year survival rate for typical carcinoids 
(TC) is better than atypical carcinoids (AC) (98% versus 
73%). Conversely, in small cell carcinomas (SCC) and large 
cell neuroendocrine carcinomas (LCNC) the five-year overall 
survival rates decrease dramatically to 5% and 13% respec-
tively.1 The diagnosis of SCC and LCNC is often straight-
forward, whereas the distinction between TC and AC can be 
difficult, and WHO classification distinguishes atypical from 
typical carcinoid on the basis of the presence of necrosis and 
with 2–10 mitoses/mm2.1 The evaluation of Ki67 proliferative 
index, that theoretically correlates with mitotic count, may be 
also helpful in distinguishing typical and atypical carcinoids 
even if WHO classification does not recognize Ki67 as a diag-
nostic parameter in lung neuroendocrine tumors and its role as 
a prognostic factor is still controversial.2,3
The oncofetal protein IMP3 is expressed during the early 
phases of embryogenesis, and its function is implicated in cell 
growth and cell migration. After birth, IMP3 is epigenetically 
silenced, with no detectable protein in normal adult tissues. 
Its re-expression is observed in a series of human malignan-
cies, including gynecological cancers like ovarian, serous 
endometrial, and cervical adenocarcinomas, as well as lung, 
pleural, gastric, colorectal, renal, and bladder cancers, but not 
in their benign counterpart. We recently identified IMP3 as a 
biomarker for distinguishing atypical premalignant endome-
triotic cysts from endometriotic cyst with reactive changes.4 
IMP3 re-expression has been correlated with decreased sur-
vival and increased risk of progression and metastases, and 
it is also considered a marker of preinvasive lesions.5,6 Two 
recent studies also demonstrated that IMP3 can induce cell 
adhesion and invasion by stabilizing CD44 mRNA, reported 
as a cell surface marker of breast and prostate cancer cells 
with stem cell traits, and can act as a key regulator of stem-like 
tumorigenic characteristics in osteosarcoma cells.7,8
There are few studies investigating IMP3 in lung 
cancers, and its expression is associated with a higher his-
tological grade, advanced stages of disease and presence 
of lymph nodes metastases. These data, in particular in the 
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neuroendocrine subgroups, are limited and without clinically 
significant correlations.8–12
The aim of our study was to evaluate the expression of 
IMP3 in a series of neuroendocrine tumors of the lung, cor-
relating with the mitotic count, Ki67 proliferation index and 
with clinical data and follow-up. To confirm the involvement of 
IMP3 in stem cell processes we correlated its expression with 
two stem cell markers, Nanog and Oct3/4 that are the most stud-
ied in lung cancers and are associated with a worse prognosis.13
MATERIALS AND METHODS
Patients and Tissue Specimens
A total of 74 patients who underwent thoracic surgery 
between 2000 and 2009 at Fondazione IRCCS Ca’ Granda – 
Ospedale Maggiore Policlinico or A.O. San Paolo Hospitals 
(Milan), with a diagnosis of neuroendocrine tumor of the 
lung, including 46 cases of typical carcinoid, nine cases of 
atypical carcinoids, 13 cases of large cell neuroendocrine car-
cinomas and six cases of small cell carcinomas were enrolled 
in this study. All patients provided written informed consent 
and archival tissue blocks of their lesions were retrieved from 
the surgical pathology archives.
All medical records were reviewed to obtain patients’ 
data, including age at diagnosis, sex, tumor location, tumor size, 
histological classification according to WHO classification and 
pathological stage (pTNM-stage) according to the seventh edi-
tion of American Joint Committee on Cancer staging manual.
The mean age of the patients was 58.3 years; 26 were 
males and 48 were females. Follow-up data were available 
for all the patients until 2013. Mean follow-up time was 65.6 
months (1–144) (Table 1).
Tissue Microarray Construction
Routinely prepared formalin-fixed paraffin-embedded 
blocks were used to construct three paraffin-embedded tissue 
microarrays. For this series, we sampled one core of normal 
lung tissue and four cores of tumoral tissue for each case.
One-millimeter diameter cores were generated using a 
semiautomatic arrayer (Alphelys Minicore2, Plaisir, France) 
and each tissue microarray block contained up to 150 cores 
with a total of 370 spots, with five spots per case. Before immu-
nohistochemistry (IHC) analyses were performed, a section 
from each tissue microarray block was cut and stained with 
hematoxylin and eosin for tissues morphological inspection.
IMP3, Nanog and Oct3/4 
Immunohistochemical Staining
Antibodies used were as follows: IMP3 antibody (M3626), 
a mouse monoclonal antibody specific for IMP3/KOC antigen, 
(clone 69.1, DAKO, Carpenteria, CA) Nanog antibody, a mouse 
polyclonal antibody, (ReproCell, Kyoto, Japan). Oct3/4 anti-
body (SC-8628), a mouse monoclonal antibody, was provided 
by Santa Cruz Biotechnology (Dallas, TX) and Ki67 antibody 
(MIB1) by DAKO. Immunohistochemistry was performed 
using the automatic system BenchMark XT (Ventana Medical 
Systems, Inc. Tucson, AZ). Reactions were revealed using the 
UltraViewTM Universal DAB, a biotin-free, multimer-based 
detection system, according to the manufacture’s instruction. 
Sections of pancreatic carcinoma known to express IMP3 and of 
human seminoma known to express NANOG and OCT3/4 were 
used as positive controls. For negative controls, we replaced the 
primary antibody with nonimmune IgG.
Evaluation of Immunohistochemical Staining
All cells of each tissue core included in the TMAs were 
evaluated, and only cases containing two or more preserved tis-
sue cores were scored. Positive staining for IMP3 was defined 
as a dark brown cytoplasmic staining pattern in the tumoral 
cells easily observed at low-power magnification (×10), and was 
scored as focal (≤30%) or diffuse (> 30%). Nanog and Oct3/4 
immunoreactivity was evaluated at nuclear and cytoplasmic lev-
els. The cases were then independently scored for the percent-
age of stained cells at the two subcellular localizations as: 0 (no 
tumor cell staining), 1 + (≤30%), 2 + (31–60%), 3 + (61–90%), 
and 4 + (> 90%). Ki67 proliferation index was evaluated at 
nuclear level and we stratified the values into three categories: 
less than or equal to 4%, 4% to 20%, and higher than 20%. The 
scores from each core stained with Nanog, Oct3/4 and Ki67 in 
the same patient were averaged to obtain a mean value.
Statistical Analysis
Differences in IMP3 or Nanog expression across tumor 
types were investigated using the chi-square test (MedCalc 
Software, Acacialaan, Ostend, Belgium). Correlation of the 
protein marker to patients’ overall or disease-free survival times 
was assessed using the Cox proportional-hazards regression, 
log rank analysis and survival curves were built according to 
the Kaplan-Meier method (MedCalc software). Probability (p) 
values less than 0.05 were considered statistically significant.
For mitotic count, cutoffs to separate patients into 
low- or high-expressor groups were generated using receiver 
operating characteristic (ROC) curves using the nonarbitrary 
criteria derived from the Youden index (J, MedCalc Software). 
The J index is defined as sensitivity plus specificity minus 1. 
We calculated the J index on the merged series of patients 
affected atypical carcinoid for which follow-up data were 
available (n = 9) to consistently test the predictive effect of the 
variable on this specific subset.
RESULTS
The frequency of IMP3-positive small cell carcino-
mas and large cell neuroendocrine carcinomas (3/12, 50% 
and 11/13, 84% respectively) was higher compared with the 
expression in typical carcinoids (5/46, 10%) and atypical car-
cinoids (5/9, 55%) (p < 0.0001).
Cox proportional-hazards regression analysis evi-
denced that IMP3-positive cases showed a marginal shorter 
time to relapse (hazard ratio = 6.1, 95% confidence interval 
2.0924–17.9168, p = 0.0010) (Fig. 1A) and a significantly 
decreased overall survival time (hazard ratio = 11.3, 95% 
confidence interval 3.1277–41.4519, p = 0.0002) (Fig. 1B) 
compared with IMP3-negative cases. No difference was 
found when correlating focal or diffuse IMP3 staining with 
disease-free and overall survival, and no statistically signifi-
cant correlations were observed with the other demographic 
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or clinicopathological parameters such as age, sex, or lymph 
node metastases.
We then assessed whether IMP3 expression was related 
to presence of potential stem cell factors, or to tumor prolif-
eration, as determined by Ki67 labeling index and mitotic 
count. In regards to stem cell markers presence, IMP3-positive 
tumors were also enriched for Nanog protein nuclear and 
cytoplasmic expression (68%, p = 0.03). Nanog was also more 
expressed by small cell carcinomas (3/6, 50%), large cell neu-
roendocrine carcinomas (4/13, 31%) and atypical carcinoids 
(3/9, 33%) than typical carcinoids (7/46, 15%) (p < 0.0001). 
Conversely, Oct3/4 expression could not be detected in all the 
analyzed series.
Next we investigated Ki67 index in the different histo-
types, in association with IMP3 expression and compared with 
mitotic rate in atypical carcinoids. Typical carcinoids showed a 
Ki67 proliferative index fewer than 4%, small cell carcinomas 
higher than 90% and large cell neuroendocrine carcinomas a 
mean proliferative index of 74.3%. We next focused on atypi-
cal carcinoids, identifying that five out of nine cases (55%) 
showed a proliferative index between 4% and 20%, whereas the 
remaining 4 a Ki67 labeling index below 4%; all the five cases 
with a Ki67 index higher than 4% showed also immunoreactiv-
ity for IMP3. In relation to patients’ outcome subset with a log 
rank analysis, simultaneous expression of the two markers was 
TABLE 1.  Cases Enrolled in the Study
No. Age Sex Histology Nodes
OS 
(months) Dead/Alive
DFS 
(months)
1 48 M TC Negative 13 Alive 13
2 48 F TC Negative 72 Alive 72
3 53 F TC Negative 144 Alive 144
4 63 F TC Negative 132 Alive 132
5 20 F TC Negative 132 Alive 132
6 68 M TC Negative 132 Alive 132
7 74 F TC Negative 12 Alive 12
8 77 F TC Negative 125 Alive 125
9 57 M TC Negative 118 Alive 118
10 74 F TC Negative 13 Alive 13
11 60 F TC Negative 108 Alive 108
12 47 M TC Negative 84 Dead 47
13 69 F TC Negative 48 Alive 48
14 30 F TC Negative 108 Alive 108
15 57 F TC Negative 84 Alive 84
16 68 M TC Negative 96 Alive 96
17 24 F TC Negative 96 Alive 96
18 24 F TC Negative 108 Alive 108
19 66 F TC Negative 108 Alive 108
20 58 M TC Positive 36 Alive 36
21 73 F TC Negative 96 Alive 96
22 61 F TC Negative 96 Alive 96
23 51 F TC Negative 96 Alive 96
24 67 F TC Negative 72 Alive 72
25 78 F TC Negative 72 Alive 72
26 82 F TC Negative 48 Alive 48
27 60 F TC Negative 72 Alive 72
28 78 F TC Negative 72 Alive 72
29 60 F TC Negative 60 Alive 60
30 73 F TC Negative 84 Alive 84
31 43 F TC Positive 60 Alive 60
32 73 M TC Negative 60 Alive 60
33 67 F TC Negative 60 Alive 60
34 31 M TC Negative 60 Alive 60
35 80 F TC Negative 60 Alive 60
36 67 F TC Negative 60 Alive 60
37 59 F TC Negative 48 Alive 8
38 69 F TC Positive 48 Alive 48
39 28 F TC Negative 48 Alive 48
40 45 M TC Negative 60 Alive 60
41 58 F TC Negative 48 Alive 48
42 51 F TC Negative 48 Alive 48
43 35 F TC Negative 47 Alive 47
44 62 F TC Negative 41 Alive 41
45 32 F TC Negative 32 Alive 32
46 56 F TC Negative 29 Alive 29
47 61 F AC Negative 6 Alive 6
48 67 F AC Negative 128 Alive 128
49 72 M AC Negative 72 Dead 72
50 53 M AC Negative 18 Dead 18
(Continued)
51 39 F AC Negative 100 Alive 100
52 59 M AC Negative 74 Dead 62
53 18 F AC Negative 67 Alive 67
54 37 F AC Positive 60 Alive 60
55 63 M AC Negative 22 Alive 10
56 66 F LNEC Positive 120 Dead 72
57 61 F LNEC Positive 120 Alive 120
58 64 M LNEC Positive 10 Dead 10
59 54 M LNEC Negative 89 Dead 89
60 56 F LNEC Positive 121 Alive 121
61 56 M LNEC Negative 19 Dead 7
62 66 M LNEC Negative 16 Dead 16
63 49 M LNEC Positive 38 Dead 38
64 75 M LNEC Negative 34 Dead 12
65 57 F LNEC Negative 24 Dead 24
66 76 M LNEC Positive 3 Dead 3
67 67 M LNEC Negative 59 Alive 59
68 49 M LNEC Positive 60 Alive 60
69 75 M SCLC Positive 121 Alive 121
70 76 M SCLC Negative 1 Alive 1
71 70 F SCLC Negative 25 Dead 15
72 81 M SCLC Positive 20 Dead 20
73 69 F SCLC Negative 83 Alive 83
74 59 M SCLC Positive 1 Dead 1
OS, overall survival; DFS, disease-free survival; TC, typical carcinoid; AC, atypical 
carcinoid; LNEC, large cell neuroendocrine carcinomas; SCLC, small cell lung cancer.
TABLE 1. (Continued)
No. Age Sex Histology Nodes
OS 
(months) Dead/Alive
DFS 
(months)
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a poor prognostic factor for overall survival (Fig. 2A, p = 0.04) 
and disease-free survival (Fig. 2B, p = 0.01) (Fig. 3).
We therefore tried to determine a mitotic count cutoff to 
find a correlation between survival and low/high mitotic rate 
in atypical carcinoids using ROC curves and the Youden index 
associated criteria (J Index), without finding a statistically sig-
nificative value.
DISCUSSION
Neuroendocrine neoplasia of the lung can be consid-
ered a spectrum of tumors with different biological behaviors, 
ranging from typical carcinoids with an excellent prognosis to 
large cell neuroendocrine carcinomas and small cell carcino-
mas with a poor outcome.
The expression of IMP3 in lung tumors has been stud-
ied in few reports,8–12 and the expression of this marker in 
neuroendocrine tumors of the lung has been investigated in 
only two studies to date.8,9 Both papers demonstrated a strong 
IMP3 positivity in high grade neuroendocrine tumors and a 
variable reactivity in typical and atypical carcinoids, without 
clinical or follow-up correlation.
In our work, the highest percentage of positive cases 
for IMP3 is found in the group of large cell neuroendocrine 
carcinomas (84%), followed by small cell carcinomas (50%), 
atypical carcinoid (55%), and typical carcinoid (11%). The 
overall survival and disease-free survival curves describe how 
IMP3-positive cases have a shorter time to relapse and overall 
survival than negative cases.
To confirm the involvement of IMP3 in processes 
linked to stem cells, as suggested by the work on osteosar-
coma cells,7 we correlated its expression with Nanog and 
Oct3/4, the two most studied stem cell markers in non-small 
FIGURE 1.  Cox proportional-hazards regression of IMP3-positive and -negative cases for disease-free survival (A, p = 0.0010) 
and overall survival (B, p = 0.0002).
FIGURE 2.  Cox proportional-hazards regression of IMP3 and Ki67 values for atypical carcinoids: cases IMP3-negative and Ki67 
< 4% are classified as “negative”, and cases IMP3-positive and Ki67 > 4% are classified as “positive” with a statistical signifi-
cance regarding the overall survival (A, p = 0.04) and disease-free survival (B, p = 0.01).
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FIGURE 3.  IMP3 and Nanog brown, cytoplasmic (IMP3) and nuclear/cytoplasmic (Nanog) staining in a typical carcinoid 
(A and B, respectively), in an atypical carcinoid (C and D, respectively) and in a large cell neuroendocrine carcinomas (E and F, 
respectively). Regarding the Nanog staining, in this case of typical carcinoid it was scored as 1 + (B), in the case of atypical carci-
noid as 3 + (D) and in the case of large cell neuroendocrine carcinomas as 2+ (TMA spot: 4×, insert: 20×).
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cell lung carcinomas. In our study, small cell carcinomas, 
large cell neuroendocrine carcinomas and atypical carcinoids 
were more frequently immunoreactive for Nanog (50%, 31%, 
and 33%, respectively) than typical carcinoid (15%). IMP3-
positive cases are more frequently positive for Nanog, with 
higher scores than IMP3 negative cases. The association 
between the expression of IMP3 and Nanog suggest that the 
former is involved in stemness processes as hypothesized in a 
recent paper about osteosarcomas.
The complete lack of Oct3/4 immunoreactivity in neu-
roendocrine tumors of the lung is an entirely new observation. 
A recent study14 described a cytoplasmically, and not nuclear, 
localized Oct3/4 variant. This pattern was observed specifi-
cally in typical carcinoids, whereas dramatically decreased 
in small cell and large cell neuroendocrine carcinomas. Our 
results confirm that, within stem cell markers, Nanog has a 
stronger potential than Oct3/4 as a tool in the diagnosis and 
prognosis of lung neuroendocrine tumors.
Immunohistochemical evaluation of Ki67 proliferation 
index can be useful especially in the differential diagnosis 
between typical carcinoid and atypical carcinoid. One of the 
first studies reported in literature showed that the proliferation 
index in atypical carcinoids is usually higher than 4%, observ-
ing a significant difference for the four-years survival rate.2
A recent systematic review by Pelosi et al.3 studied 
extensively the role of proliferative index in lung neuroen-
docrine tumors, reporting that in three large studies15–17 the 
value of Ki67 ranged from 2.3% to 4.15% in 211 TC, 9% to 
17.8% in 131 AC, 47.5% to 70.0% in 153 LCNEC, and 64.5% 
to 77.5% in 133 SCLC, in substantial agreement with the 
expected proliferation rates of these tumors.
In addition, Zahel et al. proposed to apply the grading 
system devised for digestive NETs to identify lung neuroendo-
crine tumor subpopulations with different biological behavior, 
concluding that Ki67 in addition to mitotic count could pre-
dict clinical outcome of lung carcinoids. This work, however, 
was not supported by multivariate analysis to confirm superi-
ority of this grading system in lung NETs in comparison with 
the morphological criteria illustrated in WHO classification.18
To date, cut-off values that could help in distinguish-
ing low and intermediate grade lung NETs or a lung specific 
grading system have not still been identified and correlation 
of proliferative index with clinical outcome needs more data 
to be validated. On the contrary, a study focusing on mitotic 
count in atypical carcinoid identifies that AT with a mitotic 
rate of 6 to 10/mm2 have a worse prognosis than those with 2 
to 5 mitoses/mm2.19
In our study, the analysis of Ki67 proliferative index gave 
easily predictable results for typical carcinoids, for small cell 
carcinomas and large cell carcinomas. In the atypical carcinoids 
subgroup, the 55% of the cases showed a Ki67 index between 
4% and 20%, and all these cases of were also positive IMP3. 
The two scores that we have identified for atypical carcinoid 
combining the values of IMP3 and Ki67 produced a better cor-
relation with outcome than mitotic rate alone, and allowed to 
identify subgroups at higher risk of recurrence and mortality.
These data are extremely innovative because it is still dif-
ficult to find a marker or a combination of morphological and 
immunohistochemical criteria to identify atypical carcinoids 
with poor prognosis. Our study confirms the data in literature 
concerning IMP3 as a marker of poor outcome in terms of overall 
survival and disease-free survival. Its correlation with positivity 
for Nanog suggest an implication of IMP3 in stem cell processes.
In summary, this is the first study to investigate IMP3 
expression in a subset of neuroendocrine tumors of the lung, 
and its association with a Ki67 labeling index higher than 4% 
stratifies a subset of atypical carcinoids with a higher risk of 
recurrence and mortality.
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